For the quarter ending 2026-03-31, AIDX made $353,375 in revenue. -$2,120,644 in net income. Net profit margin of -600.11%.
| Income Statement | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Revenues | 353,375 | 511,283.25* | ||
| Cost of revenues | 290,491 | 360,148* | ||
| Gross profit | 62,884 | 151,135.25* | ||
| Sales, general and administrative | 1,352,758 | 835,710.75* | ||
| Research and development | 153,482 | 148,142.25* | ||
| Total operating expenses | 1,506,240 | 983,853* | ||
| Operating loss | -1,443,356 | -832,717.75* | ||
| Interest expense | 267,008 | 39,051.75* | ||
| Interest income | 6,653 | 5,349.75* | ||
| Loss on change in fair value of warrant liability | -148,766 | 1,934.25* | ||
| Loss on issuance of convertible note | -322,359 | -70,191* | ||
| Other (expense) income, net | - | -28.75* | ||
| Total other (expense) income | -731,480 | -101,987.5* | ||
| Net loss | -2,174,836 | -934,705.25 | ||
| Dividend on preferred stock | -54,192 | - | ||
| Net loss attributable to common stockholders | -2,120,644 | - | ||
| Basic EPS | -0.28 | -0.19 | ||
| Diluted EPS | -0.28 | -0.19 | ||
| Basic Average Shares | 7,657,229 | 4,930,287 | ||
| Diluted Average Shares | 7,657,229 | 4,930,287 | ||
20 20 Biolabs, Inc. (AIDX)
20 20 Biolabs, Inc. (AIDX)